A randomized, double blind, parallel, placebo‐controlled study to investigate the efficacy of Lactobacillus paracasei N1115 in gut development of young children

Specific probiotic strains can alleviate the gastrointestinal (GI) symptoms and psychiatric comorbidities of irritable bowel syndrome (IBS). In this randomized, double-blind, placebo-controlled study, the efficacy of Lactobacillus paracasei HA-196 (L. paracasei) and Bifidobacterium longum R0175 (B. longum) in reducing the GI and psychological symptoms of IBS was evaluated in 251 adults with either constipation (IBS-C), diarrhea (IBS-D), or mixed-pattern (IBS-M). Following a 2-week run-in period, participants were randomized to one of three interventions: L. paracasei (n = 84), B. longum (n = 83) or placebo (n = 81). IBS symptoms, stool frequency and consistency and quality of life were assessed by questionnaires. The differences from baseline in the severity of IBS symptoms at 4 and 8 weeks were similar between groups. Participants in this study were classified, after randomization, into subtypes according to Rome III. Within the L. paracasei group, complete spontaneous and spontaneous bowel movement frequency increased in participants with IBS-C (n = 10) after 8 weeks of supplementation (both p < 0.05) and decreased in participants with IBS-D (n = 10, p = 0.013). Both L. paracasei and B. longum supplementation improved the quality of life in emotional well-being and social functioning compared with baseline (all p < 0.05). In conclusion, L. paracasei and B. longum may reduce GI symptom severity and improve the psychological well-being of individuals with certain IBS subtypes.

Download Full-text

Evaluation of the Effect of Lactobacillus paracasei (HF.A00232) in Children (6–13 years old) with Perennial Allergic Rhinitis: A 12-week, Double-blind, Randomized, Placebo-controlled Study

Pediatrics & Neonatology ◽

10.1016/j.pedneo.2013.10.001 ◽

2014 ◽

Vol 55 (3) ◽

pp. 181-188 ◽

Cited By ~ 17

Author(s):

Wen-Ya Lin ◽

Lin-Shien Fu ◽

Heng-Kuei Lin ◽

Chian-Yin Shen ◽

Yee-Jun Chen

Keyword(s):

Allergic Rhinitis ◽

Lactobacillus Paracasei ◽

Controlled Study ◽

Perennial Allergic Rhinitis ◽

Double Blind

Download Full-text

A Double-Blind, Placebo-Controlled Study of Atomoxetine in Young Children With ADHD

Yearbook of Psychiatry and Applied Mental Health ◽

10.1016/j.ypsy.2011.08.096 ◽

2012 ◽

Vol 2012 ◽

pp. 46-47

Author(s):

A.H. Mack

Keyword(s):

Young Children ◽

Controlled Study ◽

Double Blind ◽

Children With Adhd ◽

Double Blind Placebo

Download Full-text

Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12® and Lactobacillus paracasei ssp. paracasei, L. casei 431® in an influenza vaccination model: a randomised, double-blind, placebo-controlled study

British Journal Of Nutrition ◽

10.1017/s000711451100420x ◽

2011 ◽

Vol 107 (6) ◽

pp. 876-884 ◽

Cited By ~ 91

Author(s):

Giuliano Rizzardini ◽

Dorte Eskesen ◽

Philip C. Calder ◽

Amedeo Capetti ◽

Lillian Jespersen ◽

...

Keyword(s):

Influenza Vaccination ◽

Effective Means ◽

Innate Immune ◽

Lactobacillus Paracasei ◽

Secretory Iga ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Bifidobacterium Animalis ◽

Immune Parameters

The present study investigated the ability of Bifidobacterium animalis ssp. lactis (BB-12®) and Lactobacillus paracasei ssp. paracasei (L. casei 431®) to modulate the immune system using a vaccination model in healthy subjects. A randomised, double-blind, placebo-controlled, parallel-group study was conducted in 211 subjects (56 % females, mean age 33·2 (sd 13·1) years). Subjects consumed a minimum of 109 colony-forming units of BB-12® (capsule) or L. casei 431® (dairy drink) or a matching placebo once daily for 6 weeks. After 2 weeks, a seasonal influenza vaccination was given. Plasma and saliva samples were collected at baseline and after 6 weeks for the analysis of antibodies, cytokines and innate immune parameters. Changes from baseline in vaccine-specific plasma IgG, IgG1 and IgG3 were significantly greater in both probiotic groups v. the corresponding placebo group (L. casei 431®, P = 0·01 for IgG; P < 0·001 for remaining comparisons). The number of subjects obtaining a substantial increase in specific IgG (defined as ≥ 2-fold above baseline) was significantly greater in both probiotic groups v. placebo (BB-12®, P < 0·001 for IgG, IgG1 and IgG3; L. casei 431®, P < 0·001 for IgG1 and IgG3). Significantly greater mean fold increases for vaccine-specific secretory IgA in saliva were observed in both probiotic groups v. placebo (BB-12®, P = 0·017; L. casei 431®, P = 0·035). Similar results were observed for total antibody concentrations. No differences were found for plasma cytokines or innate immune parameters. Data herein show that supplementation with BB-12® or L. casei 431® may be an effective means to improve immune function by augmenting systemic and mucosal immune responses to challenge.

Download Full-text

Randomised double-blind placebo-controlled study of the effect of Lactobacillus paracasei NCC 2461 on skin reactivity

Beneficial Microbes ◽

10.3920/bm2013.0001 ◽

2014 ◽

Vol 5 (2) ◽

pp. 137-145 ◽

Cited By ~ 37

Author(s):

A. Gueniche ◽

D. Philippe ◽

P. Bastien ◽

G. Reuteler ◽

S. Blum ◽

...

Keyword(s):

Barrier Function ◽

Skin Barrier ◽

The Body ◽

Lactobacillus Paracasei ◽

Controlled Study ◽

Skin Barrier Function ◽

Skin Sensitivity ◽

Double Blind ◽

Double Blind Placebo ◽

Function Recovery

In recent decades, the prevalence of subjects with reactive skin has considerably increased in industrialised countries. 50% of women and 30% of men report cutaneous discomfort classified under reactive/sensitive skin. Several topical approaches have been proposed, in particular through improvement of galenic forms or protection of epidermal surface. We propose to act differently, deeply from inside the body via an innovative nutritional approach. To this purpose, Lactobacillus paracasei NCC 2461 (ST11) was selected because of its specific beneficial skin properties discovered in in vitro studies, i.e. diminution of neurogenic inflammation and promotion of the recovery of skin barrier function. We designed a randomised double-blind placebo-controlled clinical study with a two-month supplementation in two female treatment groups (n=32 per group). A capsaicin test was performed to monitor the time course of skin sensitivity. Moreover, transepidermal water loss was assessed to analyse the rate of skin barrier function recovery; dryness of the leg and roughness of the cheeks was investigated by a dermatologist as well as by self-assessment. The results of the present clinical trial show that oral supplementation with the probiotic decreases skin sensitivity and increases the rate of barrier function recovery. Thus, the data provide evidence that daily intake of ST11 could improve reactive skin condition.

Download Full-text